About 414,000 results
Open links in new tab
  1. PAPILLON (NCT04538664) is a randomized, open-label Phase 3 study evaluating the efficacy and safety of RYBREVANT ® in combination with chemotherapy, compared with chemotherapy alone, in newly diagnosed patients with advanced or metastatic NSCLC characterized by EGFR exon 20 insertion mutations.

    RYBREVANT® (amivantamab-vmjw) in Combination With Chemoth…

    www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-therapy-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302077581.html
    www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-in-combinat…
    Was this helpful?
  2. People also ask
    How many patients were enrolled in Papillon?
    About PAPILLON PAPILLON enrolled 308 patients with treatment-naive locally advanced or metastatic NSCLC and EGFR exon 20 insertion mutations.

    PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs

    ascopost.com
    Can antibiotics cure Human papillomavirus infection and gonorrhea?

    Dr. Anet Varghese

    Doctor of Medicine (MBBS) · 1 years of exp

    Gonorrhea can be treated with a single dose of 500 mg of intramuscular ceftriaxone. Although medication will stop the infection, it will not repair any permanent damage done by the disease. But, HPV infection is not effectively treated by antibiotics. There is no defenitive treatment for HPV infection.
    Q&A: Gonorrhea
    bing.com
    Will EGFR exon20ins-mutant NSCLC be enrolled in a Papillon study?
    The multicenter, global PAPILLON study is planned to open in 200 sites in 25 countries and enroll patients with EGFR Exon20ins-mutant NSCLC who are treatment-naive for metastatic disease, although limited prior EGFR TKI exposure may be allowed.

    P76.74 PAPILLON: Randomized Phase 3 Study of

    jto.org
    Can amivantamab be used as a first-line treatment for EGFR exon20ins disease?
    The primary objective of this phase 3 randomized, open-label study is to compare the efficacy of amivantamab in combination with chemotherapy (amivantamab/carboplatin/pemetrexed) versus carboplatin/pemetrexed alone as a first-line treatment for patients with EGFR Exon20ins disease.

    P76.74 PAPILLON: Randomized Phase 3 Study of

    jto.org
    What is the incidence of papillodema and viral conjunctivitis?

    Dr. Himabindu Sreenivasulu

    MBBS · 1 years of exp

    The incidence of papilledema, which refers to optic disc swelling due to increased intracranial pressure, can vary based on underlying causes. It's often associated with conditions like intracranial hypertension, and the incidence is relatively low. Viral conjunctivitis, commonly known as "pink eye, " is more common and can be caused by various viruses. Its incidence can also vary, but it's generally a frequent eye condition, especially in crowded or close-contact settings like schools or offices. Both conditions require proper diagnosis and management by a healthcare professional.
    Q&A: Eye Disease
    bing.com
    Is it possible to stop the growth of papillary thyroid cancer?

    Dr. Anukriti Pant

    Doctor of Medicine (MBBS) · 1.5 years of exp

    Yes, it is possible to stop growth of Papillary Thyroid Cancer, if distant metastasis hasn’t occurred yet. Treatment modalities available to cure Papillary Thyroid Cancer include thyroidectomy (thyroid gland removal), lobectomy (thyroid lobe removal) and radioactive ablation therapy. Post-thyroidectomy, patients need to take thyroid hormone pills (levothyroxine) daily. Close monitoring of such patients is advised both per and post operatively.
    1 more answer
    bing.com
    Feedback
  3. The New England Journal of Medicine
    https://www.nejm.org › doi › full

    Amivantamab plus Chemotherapy in NSCLC with EGFR …

    Oct 21, 2023 · We conducted the phase 3, international, randomized PAPILLON trial to assess the efficacy and safety of amivantamab–chemotherapy as compared with standard chemotherapy alone as first-line ...

  4. Johnson & Johnson
    https://www.jnj.com › media-center › press-releases

    New Data from Phase 3 PAPILLON Study Show RYBREVANT

  5. Journal of Thoracic Oncology
    https://www.jto.org › article › fulltext

    P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab …

  6. AJMC
    https://www.ajmc.com › view › papillon-…

    PAPILLON Study Meets Clinical End Point in Patients …

    Jul 17, 2023 · Amivantamab-vmjw (Rybrevant) showed efficacy in a phase 3 trial of patients with newly diagnosed advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.

  7. Targeted Oncology
    https://www.targetedonc.com › view › a…

    Amivantamab Plus Chemo Yields Positive Results in …

    Jul 18, 2023 · PAPILLON is a randomized, open-label, phase 3 study that is investigating the efficacy and safety of amivantamab in combination with chemotherapy in patients with EGFR exon 20 insertion mutated locally …

  8. Cell Press
    https://www.cell.com › med › fulltext

    Navigating challenges in EGFR exon 20 insertions: The PAPILLON …

  9. National Center for Biotechnology Information
    https://www.ncbi.nlm.nih.gov › pmc › articles

    Amivantamab in the Treatment of Metastatic NSCLC: Patient …

  10. The ASCO Post
    https://ascopost.com › issues › ...

    PAPILLON: Adding Amivantamab to First-Line …

    Dec 10, 2023 · In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with …

  11. The New England Journal of Medicine
    https://www.nejm.org › doi › pdf
    [PDF]

    Amivantamab plus Chemotherapy in NSCLC with EGFR Exon …